Article

Article

Epidemiology, Methodology, and Clinical Research in the midst of the COVID-19 pandemic

November 2, 2020
Article

Evaluating the Potential of Relapse-Free Survival as a Surrogate for Overall Survival in the Adjuvant Therapy of Melanoma with Checkpoint Inhibitors

August 10, 2020
Article

IDDI Published an Editorial on Non-Inferiority Trials

August 5, 2020
Article

Assessing Treatment Benefit in Immuno-oncology

June 9, 2020
Article

Statistical Aspects in Adjuvant and Neoadjuvant Trials for Gastrointestinal Cancer in 2020: Focus on Time-To-Event Endpoints

June 8, 2020
Article

Finding the one: How to choose a Clinical Partner in Sea of Service Providers

June 8, 2020
Article

Integration of Biomarker Validation in Clinical Development in Oncology

June 2, 2020
Article

CRO Industry update

April 28, 2020
Article

Using disease free survival as a primary endpoint in early breast cancer

June 20, 2019
Article

Surrogate endpoints create potential, require statistical validation

June 20, 2019

When every data point represents a patient, accuracy and integrity aren’t optional — they’re everything. That’s why it’s IDDI.

Start Now